ArticleCancer medicine2026
Marginal Contrast Saturation-Based Intraoperative Scoring System Predicts Objective Response to DEB-TACE: Development and Validation of a CBCT-Derived Real-Time Score.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo develop and validate a simple intraoperative scoring system based on preoperative and cone-beam CT (CBCT) features for real-time prediction of objective response (OR) by mRECIST after DEB-TACE in patients with HCC. MATERIALS AND
methodsIn this single-center retrospective study, 274 patients (with a total of 386 HCC tumors) who underwent first-session DEB-TACE from 2022 to 2024 were included. CBCT was used to assess a 5-grade marginal contrast saturation (MCS), capsule presence, vascular lake phenomenon (VLP), and other candidate imaging features. Tumor response was assessed on contrast-enhanced CT using mRECIST. Analyses were performed on a tumor basis, with tumors assigned to development (n = 286) and validation (n = 100) sets by patient-level stratified randomization (7:3). Variables associated with OR were entered into a multivariable logistic regression; β coefficients were converted into a point-based score. Model performance was evaluated in terms of discrimination and calibration using the AUROC and the Hosmer-Lemeshow test.
resultsMost patients were male (78.8%), with a mean age of 62.5 ± 9.4 years. The median tumor diameter was 3.75 cm (interquartile range [IQR], 2.50-6.50 cm). The overall objective response rate (ORR) was 67.9% (262/386). Multivariable analysis revealed four independent predictors of OR: tumor diameter, capsule presence, VLP, and MCS grade. A 1-10-point score achieved excellent discrimination in the development set and maintained high performance in the validation set, with an AUROC of 0.93 (95% confidence interval [CI]: 0.86-0.99, goodness-of-fit p = 0.46).
conclusionAn imaging-only, intraoperative scoring system incorporating tumor size, capsule, VLP, and MCS accurately predicts short-term mRECIST response after DEB-TACE, facilitating rapid decision-making and subsequent patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.